<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARTEOLOL HYDROCHLORIDE- carteolol hydrochloride solution </strong><br>Sandoz Inc.<br></p></div>
<h1>
<span class="Bold">Carteolol Hydrochloride Ophthalmic Solution USP, 1%</span><br><span class="Bold">Rx Only</span><br><span class="Bold">Sterile</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION</h1>
<p class="First">Carteolol Hydrochloride Ophthalmic Solution USP, 1% is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.</p>
<p>The chemical name for carteolol hydrochloride is (±)-5-[3-[(1,1-dimethylethyl) amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone monohydrochloride. The structural formula is as follows:</p>
<div class="Figure"><img alt="
chemical" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409&amp;name=chemical.jpg"></div>
<p>C<span class="Sub">16</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">3</span>•HCI                      Mol. Wt. 328.84</p>
<p>Each mL of sterile solution contains <span class="Bold">Active: </span>carteolol hydrochloride 10 mg (1%). <span class="Bold">Preservative: </span>benzalkonium chloride 0.05 mg (0.005%). <span class="Bold">Inactives: </span>sodium chloride, monobasic and dibasic sodium phosphate, sodium hydroxide and/or hydrochloric acid (to adjust pH to 6.0 - 8.0) and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY</h1>
<p class="First">Carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity.</p>
<p>Carteolol Hydrochloride reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. The exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated.</p>
<p>In general, beta-adrenergic blockers reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in patients in good and poor cardiovascular health. In patients with severe impairment of myocardial function, beta-blockers may inhibit the sympathetic stimulation necessary to maintain adequate cardiac function. Beta-adrenergic blockers may also increase airway resistance in the bronchi and bronchioles due to unopposed parasympathetic activity.</p>
<p>Given topically twice daily in controlled domestic clinical trials ranging from 1.5 to 3 months, Carteolol Hydrochloride produced a median percent reduction of IOP 22% to 25%. No significant effects were noted on corneal sensitivity, tear secretion, or pupil size.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE</h1>
<p class="First">Carteolol Hydrochloride Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and intraocular <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with other intraocular pressure lowering medications.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS</h1>
<p class="First">Carteolol is contraindicated in those individuals with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or with a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>); <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; second- and third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>); <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; or hypersensivity to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS</h1>
<p class="First">Carteolol has not been detected in plasma following ocular instillation. However, as with other topically applied ophthalmic preparations, Carteolol may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported with topical application of beta-adrenergic blocking agents (see <span class="Underline"><a href="#splSectionContraindications">CONTRAINDICATIONS</a></span>).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>: </span>Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.</p>
<p><span class="Bold">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>: </span>Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, Carteolol Hydrochloride should be discontinued.</p>
<p><span class="Bold">Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Allergic Bronchospasm</span>: </span>In patients with non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">allergic bronchospasm</span> or with a history of non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">allergic bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>), Carteolol Hydrochloride Ophthalmic Solution should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta<span class="Sub">2</span> receptors.</p>
<p><span class="Bold">Major Surgery: </span>The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. For these reasons, in patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents may be appropriate.</p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levarterenol (see <span class="Underline"><a href="#splSectionOverdose">OVERDOSAGE</a></span>).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus: </span>Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>: </span>Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6.1"></a><p></p>
<h2>
General</h2>
<p class="First">Carteolol Hydrochloride Ophthalmic Solution should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other beta-adrenoceptor blocking agents.</p>
<p>Use with caution in patients with known diminished pulmonary function.</p>
<p>In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil with a miotic. Carteolol has little or no effect on the pupil. When Carteolol is used to reduce elevated intraocular pressure in angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, it should be used with a miotic and not alone.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.2"></a><p></p>
<h2>
Information to the Patient</h2>
<p class="First">For topical use only. To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Protect from light.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-6.3"></a><p></p>
<h2>
Risk from <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-6.4"></a><p></p>
<h2>
<span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></h2>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-6.5"></a><p></p>
<h2>
Drug Interactions</h2>
<p class="First">Carteolol Hydrochloride Ophthalmic Solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade.</p>
<p>Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-6.6"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carteolol hydrochloride did not produce carcinogenic effects at doses up to 40 mg/kg/day in two-year oral rat and mouse studies. Test of mutagenicity, including the Ames Test, recombinant (rec)-assay, <span class="Italics">in vivo </span>cytogenetics and dominant lethal assay demonstrated no evidence for mutagenic potential. Fertility of male and female rats and male and female mice was unaffected by administration of carteolol hydrochloride dosages up to 150 mg/kg/day.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.7"></a><p></p>
<h2>
Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="splSectionPrecautionsPregnancyTerat"></a><a name="section-6.8"></a><p></p>
<h2>
Teratogenic Effects</h2>
<p class="First"><span class="Bold">Pregnancy Category C: </span>Carteolol hydrochloride increased resorptions and decreased fetal weights in rabbits and rats at maternally toxic doses approximately 1052 and 5264 times the maximum recommended human oral dose (10 mg/70 kg/day), respectively. A dose-related increase in wavy ribs was noted in the developing rat fetus when pregnant females received daily doses of approximately 212 times the maximum recommended human oral dose. No such effects were noted in pregnant mice subjected to up to 1052 times the maximum recommended human oral dose. There are no adequate and well-controlled studies in pregnant women. Carteolol Hydrochloride Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-6.9"></a><p></p>
<h2>
Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk, although in animal studies carteolol has been shown to be excreted in breast milk. Caution should be exercised when Carteolol Hydrochloride Ophthalmic Solution is administered to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-6.10"></a><p></p>
<h2>
Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-7"></a><p></p>
<h1>
ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported in clinical trials with Carteolol Hydrochloride Ophthalmic Solution.</p>
<p><span class="Bold">Ocular: </span>Transient <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, burning, tearing, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> occurred in about 1 of 4 patients. Ocular symptoms including blurred and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">cloudy vision</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span>, and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> and ocular signs including <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>, abnormal <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, and corneal sensitivity occurred occasionally.</p>
<p><span class="Bold">Systemic: </span>As is characteristic of nonselective adrenergic blocking agents, Carteolol may cause <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and decreased blood pressure (See <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>). The following systemic events have occasionally been reported with the use of Carteolol Hydrochloride Ophthalmic Solution: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p>The following additional adverse reactions have been reported with ophthalmic use of beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (nonselective) adrenergic receptor blocking agents:</p>
<p><span class="Bold">Body As a Whole: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>).</p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p><span class="Bold">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p>
<p><span class="Bold">Skin: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>)</p>
<p><span class="Bold">Endocrine: </span>Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in insulin-dependent diabetics (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>)</p>
<p><span class="Bold">Special Senses: </span>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">blepharoptosis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes (due to withdrawal of miotic therapy in some cases), <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>.</p>
<p>Other reactions associated with the oral use of nonselective adrenergic receptor blocking agents should be considered potential effects with ophthalmic use of these agents.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-8"></a><p></p>
<h1>
OVERDOSAGE</h1>
<p class="First">No specific information on emergency treatment of overdosage in humans is available. Should accidental ocular overdosage occur, flush eye(s) with water or normal saline. The most common effects expected with overdosage of a beta-adrenergic blocking agent are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>In case of ingestion, treatment with Carteolol Hydrochloride Ophthalmic Solution should be discontinued and gastric lavage considered. The patient should be closely observed and vital signs carefully monitored. The prolonged effects of carteolol must be considered when determining the duration of corrective therapy. On the basis of the pharmacologic profile, the following additional measures should be considered as appropriate:</p>
<p><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span>: </span>Administer atropine. If there is no response to vagal blockade, administer isoproterenol cautiously.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: </span>Administer a beta<span class="Sub">2</span>-stimulating agent such as isoproterenol and/or a theophylline derivative.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>: </span>Administer diuretics and digitalis glycosides as necessary.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span>Administer vasopressors such as intravenous dopamine, epinephrine or norepinephrine bitartrate.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-9"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dose is one drop of Carteolol Hydrochloride Ophthalmic Solution 1% in the affected eye(s) twice a day.</p>
<p>If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-10"></a><p></p>
<h1>
HOW SUPPLIED</h1>
<p class="First">Carteolol Hydrochloride Ophthalmic Solution USP, 1% is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 61314-238-05), 10 mL (NDC 61314-238-10) and 15 mL (NDC 61314-238-15).</p>
<p>Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">9007385-1011<br><br>SANDOZ<br><br></span>Manufactured by<br>Alcon Laboratories, Inc.<br>Fort Worth, Texas 76134 for<br>Sandoz Inc.<br>Princeton, NJ 08540<br>Printed in USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-12"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC</span> 61314-238-10</p>
<p><span class="Bold">Carteolol</span></p>
<p><span class="Bold">Hydrochloride</span></p>
<p><span class="Bold">Ophthalmic</span></p>
<p><span class="Bold">Solution USP</span></p>
<p><span class="Bold">1%</span></p>
<p><span class="Bold">Rx only<br><br></span>STERILE<br><span class="Bold">10 mL</span></p>
<p><span class="Bold">SANDOZ</span></p>
<p>    </p>
<p></p>
<div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409&amp;name=label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARTEOLOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">carteolol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61314-238</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARTEOLOL HYDROCHLORIDE</strong> (CARTEOLOL) </td>
<td class="formItem">CARTEOLOL HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61314-238-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61314-238-10</td>
<td class="formItem">10 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:61314-238-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075476</td>
<td class="formItem">01/05/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sandoz Inc.
							(005387188)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f507500a-ed39-301f-8e85-ae898a81a313</div>
<div>Set id: 571fe550-399d-4296-835c-37aa1ab9b409</div>
<div>Version: 3</div>
<div>Effective Time: 20120307</div>
</div>
</div> <div class="DistributorName">Sandoz Inc.</div></p>
</body></html>
